Among the many molecularly defined checkpoint proteins22,23, one of the most studied in lung cancer clinical trials is programmed cell death 1 (PD-1) receptor, also known as CD279 (cluster of differentiation 279), and its ligand (PD-L1), also known as B7-H1 or CD27413,.24 The gene discussed is PDCD1; the disease is lung carcinoma.